Table 2.

Comparison of motor, dyskinesia, gait and balance changes from baseline between the three groups at 1-month follow-up

	ZNS 25 mg (no. = 25)	ZNS 50 mg) (no. = 18)	Placebo (no. = 26)	Kruskal–Wallis H	ZNS 25 mg vs ZNS 50 mg	ZNS 25 mg vs placebo	ZNS 50 mg vs placebo
				P value	P value	P value	P value
MDS-UPDRS TS OFF	3 (10)	6 (16)	1.00 (8)	0.158
MDS-UPDRS TS ON	5 (9)	4 (10)	− 0.50 (5)	0.012*	0.834	0.007*	0.021*
MDS-UPDRS Part I (nM-EDL)	0 (3)	2 (4)	− 1 (2)	0.076
MDS-UPDRS Part II (M-EDL)	2 (3)	2 (5)	1 (3)	0.320
MDS-UPDRS Part III OFF	1 (7)	5 (11)	1 (5)	0.751
MDS-UPDRS Part III ON	2 (7)	0 (6)	1 (4)	0.084
Rigidity OFF	0 (2)	1 (3)	0 (1)	0.392
Rigidity ON	1 (2)	0 (3)	0 (2)	0.163
Bradykinesia OFF	1 (3)	0 (5)	0 (2)	0.953
Bradykinesia ON	1 (4)	1 (2)	0 (3)	0.603
Tremors OFF	1 (4)	0 (3)	0 (1)	0.39
Tremors ON	1 (2)	0 (1)	0 (1)	0.009*	0.021*	0.005*	0.663
MDS-UPDRS Part IV	0 (1)	1 (2)	0 (1)	0.012*	0.009*	0.726	0.010*
MDS-UDysRS	− 1 (3)	0 (1)	0 (2)	0.378
BBS ON	0 (2)	0 (2)	0 (1)	0.675
NFOG ON	0 (0)	0 (2)	0 (0)	0.015*	0.01*	0.895	0.011*
10-MWT Comfortable speed ON	0.0022 (0.15)	0.024 (0.06)	0.0005 (0.08)	0.549
10-MWT Maximum speed ON	0.042 (0.17)	0.04 (0.09)	0.017 (0.09)	0.087

Data are shown as median (IQR)

MDS-UPDRS Movement Disorder Society-Unified Parkinson Disease Rating Scale, TS total score, nM-EDL Nonmotor aspects of experiences of daily living, M-EDL Motor aspects of experiences of daily living, MDS-UDysRS Movement Disorder Society-Unified Dyskinesia Rating Scale, 10-MWT: 10 m walking test, BBS Berg Balance Scale, NFOG new freezing of gait questionnaire, ZNS zonisamide

^*P value is significant if < 0.05